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Background.  Clinical trials have demonstrated that immediate initiation of antiretroviral therapy (ART) reduces AIDS-related 
morbidity and mortality. We tested the hypothesis that initiating ART ≤30 days after human immunodeficiency virus (HIV) diagno-
sis would be associated with reduced mortality among people living with HIV (PLWH) with CD4 counts >500 cells/μL.
Methods. PLWH enrolled in the Chinese National HIV Information System between January 2012 and June 2014 with CD4 
counts >500 cells/μL were followed for 12 months. Cox proportional hazards model was used to determine hazard ratios (HRs) for 
PLWH who initiated ART after HIV diagnosis. ART initiation was treated as a time-dependent variable.
Results. We enrolled 34 581 PLWH with CD4 >500 cells/μL; 1838 (5.3%) initiated ART ≤30 days after diagnosis (immediate 
ART group), and 19 deaths were observed with a mortality rate of 1.04 per 100 person-years (PY). Fifty-eight deaths were docu-
mented among the 5640 PLWH in the delayed ART group with a mortality rate of 2.25 per 100 PY. There were 713 deaths among the 
27 103 PLWH in the no ART group with a mortality rate of 2.39 per 100 PY. After controlling for potential confounding factors, ART 
initiation at ≤30 days (adjusted HR, 0.37 [95% confidence interval, .23–.58]) was a statistically significant protective factor.
Conclusions. We found that immediate ART is associated with a 63% reduction in overall mortality among PLWH with CD4 
counts >500 cells/μL in China, supporting the recommendation to initiate ART immediately following HIV diagnosis.
Keywords. HIV/AIDS; antiretroviral therapy; treatment initiation; CD4 count; mortality. 
Over the past 2 decades, combination antiretroviral therapy 
(ART) has been a cornerstone of the response to the epidemic 
of human immunodeficiency virus (HIV) infection that causes 
AIDS [1–3]. The scale-up of ART has resulted in substantial 
reductions in AIDS-related mortality and morbidity, as well as 
reduced HIV transmission [4–8]. Nevertheless, less than half 
of the estimated 36.7 million people living with HIV (PLWH) 
were receiving ART in 2015 [9].
Historically, there has been an early consensus that PLWH 
who had an AIDS-defining illness should initiate ART immedi-
ately. For those who had not yet progressed to AIDS, the World 
Health Organization (WHO) has recommended that CD4+ 
T-lymphocyte thresholds guide the timing of ART initiation 
[10]. However, observational studies, predominantly carried 
out in resource-rich settings [11], have found that ART initi-
ation among PLWH with CD4 counts >500 cells/μL was asso-
ciated with substantial clinical benefits, and this has now been 
confirmed by prospective randomized trials [12–15]. Taken 
together with the results of the HPTN 052 trial [7, 8], showing 
the sustained ability of ART to prevent sexual transmission of 
HIV, these findings led the WHO to revise their recommen-
dation in September 2015, now completely removing the CD4 
count threshold, such that ART is globally recommended for all 
PLWH [16].
Standard of care for all those diagnosed with HIV infec-
tion in China includes free CD4 testing each year, with the 
first CD4 test offered soon after diagnosis. From 2008 to 2014, 
the primary criterion for entry into the Chinese National 
Free Antiretroviral Treatment Program (NFATP) was CD4 
count ≤350 cells/μL. During this time, exceptions to the CD4 
threshold of ≤350 cells/μL in the NFATP included patients 
with coinfections, and prevention of mother-to-child trans-
mission [17]. In 2011, the NFATP added a recommendation 
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that ART be offered to all PLWH in serodiscordant relation-
ships, regardless of CD4 cell count [17]. In 2012, a special 
national project for the “Prevention and Treatment of Major 
Infectious Diseases” was launched, wherein the National 
Center for AIDS/STD Control and Prevention (NCAIDS) 
of the Chinese Center for Disease Control and Prevention 
(China CDC) implemented a series of cluster-randomized 
trials among key populations, including men who have sex 
with men, serodiscordant couples, people who inject drugs, 
and commercial sex workers. The targeted outcome was early 
identification of HIV infection and immediate ART initiation 
regardless of CD4 cell count. Thus, PLWH participating in the 
study were exempt from the standard-of-care CD4 threshold 
for ART initiation.
The primary aim of the present study was to examine mor-
tality and its determinants among a cohort of newly diagnosed 
PLWH with first CD4 count >500 cells/μL. Participants were 
followed for 1 year to examine the impact of immediate ART 
initiation on mortality among PLWH with high CD4 counts, 
compared to those with delayed ART initiation and to those 
who remained ART naive. Secondarily, we also sought to 
describe causes of death within our cohort.
METHODS
Study Design and Setting
This nationwide, observational cohort study was designed to 
examine mortality among patients who received confirmed 
diagnoses of HIV infection between 1 January 2012 and 30 June 
2014 and had a CD4 count >500 cells/μL. Mortality and fac-
tors associated with mortality were assessed at 1 year. A  flow 
diagram illustrating the study design is shown in Figure 1. The 
treatment setting was China’s NFATP. This program, as well as 
treatment regimens (eg, drug combinations used, dosage, and 
administration) and follow-up protocols for enrolled patients, 
have been described previously [17, 18].
Data Source
Data were extracted from China’s Web-based national data-
base for real-time collection and maintenance of information 
related to the HIV epidemic. This system, called the HIV/AIDS 
Comprehensive Response Information Management System 
(CRIMS), has been described elsewhere [19–21]. Because 
screening for inclusion was nationwide and included all identi-
fied cases, sample size was not initially defined.
Data Collection and Inclusion Criteria
All CRIMS records of persons with a confirmed diagnosis of 
HIV infection between 1 January 2012 and 30 June 2014 were 
extracted and then further screened for study eligibility crite-
ria. In addition to a confirmed new HIV diagnosis, PLWH were 
included if they were 18 years or older at the time of diagno-
sis, had a CD4 test result within 1 year of diagnosis, had base-
line (pre-ART) CD4 count of >500 cells/μL, and had reported 
having acquired HIV through heterosexual contact, male-to-
male sexual contact, or injection drug use. These transmission 
Figure 1. Flow diagram depicting study design and development of the cohort. Abbreviations: ART, antiretroviral therapy; HIV, human immunodeficiency virus.
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routes accounted for >90% of newly diagnosed HIV infections 
in China during this time period [22].
All eligible records were extracted and de-identified. Each 
study participant was followed from the date of their first CD4 
test for 12  months afterward or the date of death, whichever 
came first. As illustrated in Figure 1, participants were stratified 
by timing of ART initiation relative to the date of confirmed 
HIV diagnosis (≤30 days after HIV diagnosis referred to as the 
immediate ART group; >30 days after HIV diagnosis referred to 
as the delayed ART group; and PLWH who did not start ART 
within 1 year referred to as the no ART group).
Mortality and Causes of Death
The main outcome measure was all-cause mortality. Dates and 
causes of death were obtained from clinical records. AIDS-
related causes of death were defined by China CDC medical 
guidelines [23]. Non-AIDS-related causes of death included all 
other causes.
Statistical Analysis
Continuous variables are presented using median and inter-
quartile range (IQR), and categorical variables are presented 
using number and percentage. Because of the very large number 
of patients in our cohort, even very small differences between 
subgroups would likely result in P values reaching statistical sig-
nificance. However, these small differences would not necessar-
ily be meaningful. Therefore, we focused only on differences of 
≥5% between groups being compared.
Observed time, in person-years (PY), was calculated for 
participants who contributed to the study observation. As the 
median time interval between confirmed HIV diagnosis and 
first CD4 test was only 14 days (IQR, 3–57 days), CD4 test date 
was selected as the start of observed time. Thus, observed time 
was calculated as the difference between the date of first CD4 
test and the date of death or the end of the follow-up period, 
whichever came first. Mortality rate was calculated as the sum 
of deaths divided by the sum of observed time in PY. Due to sur-
vival bias, patients who accepted ART were always alive before 
ART initiation. Thus, ART status was treated as a time-de-
pendent variable, meaning that those who accepted ART were 
a part of the no ART group until ART initiation. Individuals 
contributed person-time (and deaths) to the immediate ART 
group after they began ART, provided ART initiation occurred 
within 30 days of the start. Individuals contributed person-time 
to the delayed ART group after they began ART, provided ART 
initiation occurred after 30 days from the start but before 1 year. 
A multivariate Cox proportional hazards regression model was 
constructed to assess hazard ratios (HRs) for the study variable 
ART status, and for demographic variables and HIV clinical var-
iables. The immediate ART variable in the regression model was 
considered time dependent. That is, it was set to 0 before ART 
initiation, and to 1 after ART initiation, provided it occurred 
before the end of day 30. Similarly, the delayed ART variable 
was set to 0 before ART initiation, and to 1 after ART initiation, 
provided it occurred after day 30, but within 1 year. Adjusted 
HRs for the study variable were generated to identify prognostic 
risk of death by controlling potential confounding bias caused 
by demographic variables and HIV clinical variables.
All P values presented are 2-sided, and P < .05 was considered 
statistically significant. All analyses were performed using SAS 
software version 9.1.3 (SAS Institute).
Ethical Considerations
The study protocol was reviewed and approved by the 
Institutional Review Board of NCAIDS, China CDC. As patients 
entering CRIMS sign informed consent at time of enrollment, 
no further informed consent was required for this study. All 
patient records were de-identified prior to data analysis.
RESULTS
A full 212 402 individual records with a date of confirmed HIV 
diagnosis between 1 January 2012 and 30 June 2014 were avail-
able for the study. A total of 34 581 individuals (16.3%) met the 
eligibility criteria and were included in the final study cohort. 
Development of the cohort is illustrated in Figure 1.
Characteristics of the Cohort
Characteristics of the entire study cohort, as well as individual 
subgroups thereof, are shown in Table 1. The median age of 
patients in the cohort was 32 years (IQR, 25–42 years). A major-
ity were male (75.0%), Han Chinese (72.2%), had junior middle 
school education or less (63.7%), were single, divorced, or wid-
owed (60.8%), and self-reported acquisition of HIV infection 
via heterosexual contact (59.9%). Median baseline CD4 count 
was 616 cells/μL (IQR, 549–732 cells/μL).
Characteristics of Groups Stratified by Timing of ART Initiation
Among 34 581 PLWH, 1838 (5.3%) initiated ART within 30 days 
of diagnosis and were included in the immediate ART group 
and 5640 (16.3%) initiated ART >30 days after diagnosis and 
were included in the delayed ART group. The remaining 27 103 
PLWH (78.4%) formed the no ART group. A larger proportion 
of PLWH in the immediate ART group were female (36.9% vs 
28.1% for the delayed ART group and 23.6% for the no-ART 
group), ethnic minorities (36.0% vs 28.6% and 27.1%), less well 
educated (junior middle school or less: 72.0% vs 64.4% and 
63.0%), married or cohabitating (57.4% vs 49.8% and 35.8%), 
and reported heterosexual contact as their mode of HIV acqui-
sition (76.7% vs 64.1% and 57.9%).
Mortality and Causes of Death
Deaths and mortality rates are shown in Table 2. The 34 581 
PLWH in the study cohort were followed from the date of their 
first CD4 test until 1 year after or death, whichever was first, 
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resulting in a total observed time of 34 188 PY. Seven hundred 
ninety deaths of 34 581 (2.3%) were documented, for an overall 
mortality rate of 2.31 per 100 PY.
Among the 1838 PLWH in the immediate ART group, 19 
deaths were observed within 1828 PY of observed time, for a 
mortality rate of 1.04 per 100 PY. Fifty-eight deaths were doc-
umented among the 5640 PLWH in the delayed ART group 
within 2583 PY of observed time, for a mortality rate of 2.25 per 
100 PY. Finally, 713 deaths were documented among the 27 103 
PLWH in the no ART group within 29 778 PY of observed time, 
for a mortality rate of 2.39 per 100 PY.
The causes of death are presented in Table 3. Causes of death 
for a majority of the 790 PLWH were documented as non-AIDS-
related complications (76.3%). A further 8.6% of PLWH had no 
cause of death documented or an unclassified cause of death listed 
in their record. AIDS-related complications were identified as the 
cause of death for 15.1%. In the immediate ART group, no AIDS-
related causes of death were documented. The most common 
non-AIDS cause was cardiovascular disease (36.8%). Among 
those in the delayed ART group, 41.4% died from AIDS-related 
causes, whereas 55.1% died from non-AIDS-related causes. In 
the no ART group, a majority of deaths were documented as 
having non-AIDS-related causes (77.6%), the most frequent of 
which were other diseases (13.9%), respiratory disease (13.1%), 
and non-disease-related deaths/accidents (12.9%).
Factors Associated With Death
Factors associated with death within 1 year are presented in 
Table 2. Higher risk of death was associated with older age (30–
49 years: adjusted HR, 2.03, P < .001; ≥50 years: adjusted HR, 
6.10, P < .001), being male (adjusted HR, 1.90, P < .001), having 
only a junior middle school education or less (adjusted HR, 1.85, 
P < .001), and having been infected via heterosexual contact 
(adjusted HR, 4.16, P < .001) or injection drug use (adjusted HR, 
5.07, P < .001). As far as the timing of ART initiation, imme-
diate ART (initiating within 30 days of diagnosis) provided the 
Table  1. Baseline Characteristics of the Entire Study Cohort and of Each Subgroup Based on Antiretroviral Therapy Timing After Confirmed Human 
Immunodeficiency Virus Diagnosis
Characteristics Entire Study Cohort
ART Timing After Confirmed HIV Diagnosis
Immediate ART
(≤30 d)
Delayed ART
(>30 d)
No ART
(>1 y)
Total 34 581 (100.0) 1838 (100.0) 5640 (100.0) 27 103 (100.0)
Age, y
 Median (IQR) 32 (25–42) 34 (27–46) 33 (26–45) 31 (25–41)
 18–29 14 771 (42.7) 653 (35.5) 2110 (37.4) 12 008 (44.3)
 30–49 14 976 (43.3) 816 (44.4) 2565 (45.5) 11 595 (42.8)
 ≥50 4834 (14.0) 369 (20.1) 965 (17.1) 3500 (12.9)
Sex
 Male 25 927 (75.0) 1160 (63.1) 4058 (72.0) 20 709 (76.4)
 Female 8654 (25.0) 678 (36.9) 1582 (28.1) 6394 (23.6)
Ethnicity
 Han 24 969 (72.2) 1176 (64.0) 4029 (71.4) 19 764 (72.9)
 Other 9612 (27.8) 662 (36.0) 1611 (28.6) 7339 (27.1)
Education level
 Junior middle school or less 22 039 (63.7) 1323 (72.0) 3630 (64.4) 17 086 (63.0)
 Senior middle school or 
higher
12 542 (36.3) 515 (28.0) 2010 (35.6) 10 017 (37.0)
Marital status
 Single, divorced, or widowed 21 019 (60.8) 783 (42.6) 2829 (50.2) 17 407 (64.2)
 Married or cohabiting 13 562 (39.2) 1055 (57.4) 2811 (49.8) 9696 (35.8)
Transmission route
 Heterosexual contact 20 713 (59.9) 1409 (76.7) 3615 (64.1) 15 689 (57.9)
 Male-to-male sexual contact 10 167 (29.4) 348 (18.9) 1674 (29.7) 8145 (30.1)
 Injecting drug use 3701 (10.7) 81 (4.4) 351 (6.2) 3269 (12.1)
Baseline CD4 count, cells/μL
 Median (IQR) 616 (549–732) 596 (538–694) 594 (540–692) 623 (552–744)
Time from diagnosis to CD4 test, d
 Median (IQR) 14 (3–57) 6 (0–20) 11 (1–39) 18 (4–65)
Time from CD4 to ART, d
 Median (IQR) 10 (4–18) 197 (109–283)
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: ART, antiretroviral treatment; HIV, human immunodeficiency virus; IQR, interquartile range.
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strongest protection against death (adjusted HR, 0.37, P < .001), 
while delayed ART (initiating after 30 days of diagnosis, but 
within 1 year) provided more modest protection (adjusted HR, 
0.74, P = .040) relative to not receiving ART within the first year.
DISCUSSION
Our results demonstrate that PLWH with a CD4 count >500 cells/
μL who initiated ART within 30 days of diagnosis (immediate ART 
group) experienced a 63% decrease in mortality. Additional risk 
factors for mortality in this study were older age, being male, hav-
ing a lesser education, and becoming infected via injection drug 
use or heterosexual contact. A majority of deaths observed were 
attributed to non-AIDS-related complications. Our results confirm 
those from the recent START (strategic timing of antiretroviral 
treatment) and TEMPRANO (early antiretroviral treatment and/
or early isoniazid prophylaxis against tuberculosis in HIV-infected 
adults – ANRS 12136 TEMPRANO) studies [12, 15], and further 
indicate that these results are also generalizable to China.
The push for earlier ART initiation has recently been formal-
ized through policy recommendations [16]. Arguments to delay 
ART initiation based on the use of a CD4 cell count threshold 
include concerns about drug resistance, side effects, resource 
allocation, and adherence [24–29]. However, research studies 
have definitively concluded that the potential clinical and public 
health benefits of immediate ART initiation far outweigh the 
risks. Our results highlight the urgency of immediate ART ini-
tiation among PLWH with high CD4 cell counts.
HIV-infected, ART-naive patients with high CD4 cell counts 
still experience elevated mortality compared with the general 
population [30, 31]. Non-AIDS events remain common among 
this group [32, 33], and non-AIDS-related mortality can exceed 
AIDS-related mortality [34]. In settings outside of China, a 
high proportion of non-AIDS mortality has been attributed to 
illicit drug use, suicide, unintentional injury, and violence [35, 
36]. A cohort study of ART-naive PLWH with CD4 count >350 
cells/μL in Europe and North America found that only 14.6% 
Table 2. Cox Proportional Hazards Regression Models for Mortality Rates and Associated Risk Factors
Characteristic
Entire Study Cohort, 
No. (%)
Deaths,
No. (%)
Observed Timea, 
PY
Mortality
Rate per 100 PY
Unadjusted
HR (95% CI) P Value
Adjusted
HR (95% CI) P Value
Total 34 581 (100.0) 790 (100.0) 34 188 2.31
Age, y
 18–29 14 771 (42.7) 122 (15.4) 14 718 0.83 1.00 1.00
 30–49 14 976 (43.3) 334 (42.3) 14 809 2.26 2.72 (2.21–3.35) <.001 2.03 (1.64–2.52) <.001
 ≥50 4834 (14.0) 334 (42.3) 4661 7.17 8.65 (7.03–10.64) <.001 6.10 (4.87–7.64) <.001
Sex
 Male 25 927 (75.0) 629 (79.6) 25 616 2.46 1.31 (1.10–1.56) .002 1.90 (1.59–2.27) <.001
 Female 8654 (25.0) 161 (20.4) 8573 1.88 1.00 1.00
Ethnicity
 Han 24 969 (72.2) 543 (68.7) 24 692 2.20 1.00 1.00
 Other 9612 (27.8) 247 (31.3) 9497 2.60 1.18 (1.02–1.38) .03 1.09 (.93–1.28) .30
Education level
 Junior middle 
school or less
22 039 (63.7) 688 (87.1) 21 691 3.17 3.89 (3.16–4.78) <.001 1.85 (1.48–2.31) <.001
 Senior middle 
school or higher
12 542 (36.3) 102 (12.9) 12 498 0.82 1.00 1.00
Marital status
 Single, divorced, or 
widowed
21 019 (60.8) 411 (52.0) 20 814 1.97 1.00 1.00
 Married or 
cohabitating
13 562 (39.2) 379 (48.0) 13 375 2.83 1.44 (1.25–1.65) <.001 0.88 (.76–1.02) .928
Transmission route
 Heterosexual 
contact
20 713 (59.9) 623 (78.9) 20 394 3.05 7.04 (5.19–9.56) <.001 4.16 (2.99–5.77) <.001
 Male-to-male sex-
ual contact
10 167 (29.4) 44 (5.6) 10 145 0.43 1.00 1.00
 Injection drug use 3701 (10.7) 123 (15.6) 3649 3.37 7.77 (5.51–10.97) <.001 5.07 (3.49–7.35) <.001
ART statusb
 Immediate ART 1838 (5.3) 19 (2.4) 1828 1.04 0.44 (.28–.69) <.001 0.37 (.23–.58) <.001
 Delayed ART 5640 (16.3) 58 (7.3) 2583 2.25 0.80 (.61–1.05) .11 0.74 (.57–.98) .04
 No ART 27 103 (78.4) 713 (90.3) 29 778 2.39 1.00 1.00
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; HR, hazard ratio; PY, person-years.
aObserved time, in PY, was calculated as beginning on the date of first CD4 test, and ending at 1 year or on the date of death, whichever came first.
bART was treated as the time-dependent variable; immediate ART means ART was initiated within 30 days of confirmed human immunodeficiency virus (HIV) diagnosis; delayed ART means 
ART was initiated >30 days after diagnosis, but within 1 year; no ART means that ART was never initiated in the 1 year after HIV diagnosis.
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of deaths were categorized as AIDS-related, whereas 44.9% 
were categorized as non-AIDS-related (40.6% of deaths in the 
study were due to unknown causes) [30]. In our study, 94.7% 
of deaths in the immediate ART group, 55.1% in the delayed 
ART group, and 77.6% in the no ART group were classified as 
non-AIDS-related deaths [34]. Consistent with other studies, 
the most common causes of death observed were cardiovas-
cular disease, liver disease, non-AIDS-defining malignancies, 
overdose, suicide, and accidental deaths [33, 35–38].
In addition to the direct benefit of ART for survival, it is also 
likely that regular follow-up and comprehensive care services 
associated with ART use contributed to the decreased mortality 
observed. After ART initiation, patients entered into the stable 
care system and received multidisciplinary services including 
regular medical visits as well as psychosocial support [39, 40]. 
ART clinics provided chronic disease management and cancer 
and cardiovascular disease screening, which may have contrib-
uted to the improvement in health outcomes observed [41–43]. 
Our study design did not allow us to discriminate the relative 
contribution of ART vs close medical monitoring. However, the 
fact that a similar benefit in clinical outcomes was observed in 
randomized clinical trials [12, 15], where clinical follow-up was 
standardized between study arms, suggests that our conclusion 
regarding the benefit of ART at high CD4 cell counts is valid.
Other risk factors for mortality in this study included older 
age, being male, acquiring HIV through injection drug use or 
heterosexual transmission, and low educational attainment. In 
China, HIV incidence has been increasing among older males, 
particularly in rural areas, who are mainly infected through 
engaging in commercial sex [44]. Older HIV-infected individ-
uals are more likely to present with comorbidities that increase 
their risk of death [45]. Mortality was highest among injection 
drug users, which is related to a variety of factors including 
delayed ART initiation, poor ART adherence, concomitant 
drug use, and comorbidities such as depression and hepatitis C 
virus infection [46].
In contrast to other studies that have examined ART initi-
ation at high CD4 counts [14], an important strength of this 
study was that all participants who initiated ART in our cohort 
did so when their CD4 count was >500 cells/μL. Nevertheless, 
our study had several limitations. As with any observational 
study, our data should be interpreted with caution, as partici-
pants may have had individual circumstances that could have 
influenced their treatment initiation decisions, including med-
ical comorbidities. Also, because we used routine care data, we 
did not have access to some potentially informative variables, 
such as viral load results, details on complications, and, in some 
cases, causes of death. Moreover, the delayed ART group and 
no ART group were subject to a survival bias, as the immedi-
ate ART group always included persons who lived long enough 
to initiate ART. To partially avoid this bias, we treated ART as 
a time-dependent variable. Finally, as the start of follow-up 
time was date of CD4 test, and those in the delayed ART group 
tended to have longer median durations between CD4 testing 
and ART initiation, the shorter time on ART during follow-up 
may have contributed to poorer outcomes in this group.
CONCLUSIONS
Our results demonstrate that immediate ART initiation within 
30 days among PLWH with CD4 counts >500 cells/μL is asso-
ciated with a 63% reduction in overall mortality. Our results 
highlight the significant negative impact of delays in ART initi-
ation in a real-world setting in China. Our findings are consist-
ent with the results of recent randomized controlled trials and 
demonstrate that these results are generalizable. Furthermore, 
our results support the urgent need to increase the number 
of PLWH identified early and started on effective, long-term 
Table 3. Causes of Death During Follow-up
Cause of Death
Entire Study 
Cohort
ART Timing After Confirmed HIV 
Diagnosis
Immediate 
ART
(≤30 d)
Delayed ART
(>30 d)
No ART
(>1 y)
Total 790 (100.0) 19 (100.0) 58 (100.0) 713 (100.0)
AIDS-related 119 (15.1) 0 (0.0) 24 (41.4) 95 (13.3)
 AIDS-defining cancer 10 (1.3) 1 (1.7) 9 (1.3)
 CNS infection 3 (0.4) 1 (1.7) 2 (0.3)
 Tuberculosis 15 (1.9) 2 (3.5) 13 (1.8)
 Cryptococcal meningitis 4 (0.5) 1 (1.7) 3 (0.4)
 Herpes virus infection 4 (0.5) 4 (0.6)
 Wasting syndrome 6 (0.8) 2 (3.5) 4 (0.6)
 Candidiasis 5 (0.6) 2 (3.5) 3 (0.4)
 Recurrent pneumonia 5 (0.6) 1 (1.7) 4 (0.6)
 Pneumocystis 
pneumonia
14 (1.8) 3 (5.2) 11 (1.5)
 Cryptosporidiosis 2 (0.3) 1 (1.7) 1 (0.1)
 Other infections 12 (1.5) 12 (1.6)
 Other 39 (4.9) 10 (17.2) 29 (4.1)
Non-AIDS-related 603 (76.3) 18 (94.7) 32 (55.1) 553 (77.6)
 Non-AIDS-defining 
cancer
80 (10.1) 4 (6.9) 76 (10.7)
 Cardiovascular disease 94 (11.9) 7 (36.8) 6 (10.3) 81 (11.4)
 Overdose of illicit drugs 45 (5.7) 1 (5.3) 1 (1.7) 43 (6.0)
 Suicide 35 (4.4) 2 (10.5) 2 (3.5) 31 (4.3)
 Hepatitis B or C virus 12 (1.5) 1 (5.3) 1 (1.7) 10 (1.4)
 Respiratory disease 98 (12.4) 3 (15.8) 2 (3.5) 93 (13.1)
 Metabolic disease 10 (1.3) 2 (10.5) 2 (3.5) 6 (0.8)
 Gastrointestinal disease 22 (2.8) 1 (1.7) 21 (3.0)
 Medicine-related events 1 (0.1) 1 (0.1)
 Other diseases 107 (13.6) 2 (10.5) 6 (10.3) 99 (13.9)
 Non-disease-related 
death/accident
99 (12.5) 7 (12.0) 92 (12.9)
Unknown 68 (8.6) 1 (5.3) 2 (3.5) 65 (9.1)
 Unclassified 66 (8.3) 1 (5.3) 2 (3.5) 63 (8.8)
 Missing 2 (0.3) 0 (0.0) 0 (0.0) 2 (0.3)
Data are presented as No. (%) unless otherwise indicated.
Abbreviations: ART, antiretroviral therapy; CNS, central nervous system; HIV, human immu-
nodeficiency virus.
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ART immediately [13, 47], as predicated by the United Nations 
90-90-90 targets [38, 48, 49].
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